Timothée Olivier, MD· @Timothee_MD · X·· 16 hours agoScore60
Body · original
#ESMO26 tomorrow the 6-y survival results of the NATALEE trial will be presented in Madrid, 2:25 pm trial = 3 years adjuvant ribociclib in patients with HR+ HER2- early breast cancer. what will be key? 👉 Post-protocol data see why in my talk today at @MDAnderson_ES! https://t.co/L2GO43fOYR
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: Timothée Olivier, MD · x.com